The Therapeutic Role of Rho Kinase Inhibitor, Fasudil, on Pulmonary Hypertension; a Systematic Review and Meta-Analysis

Abstract

Background Pulmonary hypertension (PH) is a pathophysiological disorder, which involves multiple clinical conditions such as the upregulation of the Rho/ROCK signaling pathway. On the other hand, fasudil as a Rho kinase inhibitor has been investigated in the treatment of PH in some clinical studies.

Objectives The present systematic review and meta-analysis aimed to evaluate the human clinical trials regarding the efficacy of fasudil in the management of PH.

Methods Databases were searched with pre-defined search terms, up to December 2021. Efficacy measures were such as mean pulmonary arterial pressure (mPAP), systolic PAP (sPAP), pulmonary vascular resistance (PVR), systolic vascular resistance (SVR) and cardiac index (CI).

Results A total of 12 studies involving 575 PH patients were included in our research. Eight short-term trials and four mid-term trials were found (no clinical trials on the long-term effects). Short-term trials had a before-after study design and measuring pulmonary hemodynamic parameters’ intervention revealed a statistically significant improvement of mPAP, sPAP, PVR, SVR, and CI in the meta-analysis of five eligible studies. Three mid-term trials also revealed improvement in some pulmonary hemodynamic parameters with fasudil and in another mid-term trial, fasudil significantly decreased rehospitalization and mortality in PH patients. No serious adverse effects with fasudil were reported in these trials.

Conclusion Fasudil therapy is efficacious and probably safe in the improvement of some hemodynamics in PH patients along short and mid-term periods. However, long-term randomized controlled trials comparing fasudil with placebo and other treatments are warranted for confirmation of these benefits.

Key words

Rho kinase inhibitor - Fasudil - Pulmonary hypertension - Meta-analysis

Publikationsverlauf

Eingereicht: 24. März 2022

Angenommen: 29. Mai 2022

Artikel online veröffentlicht:
10. Oktober 2022

• References

• 1 Hoeper MM, Humbert M. The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally! In: Eur Respiratory Soc. 2019
• 2 Galiè N, Humbert M, Vachiery J-L. et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Respiratory Journal 2015; 46: 903-975
• 3 Oliveira AC, Richards EM, Raizada MK. Pulmonary hypertension: pathophysiology beyond the lung. Pharmacological research 2020; 151: 104518
• 4 Humbert M, Guignabert C, Bonnet S. et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. European Respiratory Journal 2019; 53: 1801887
• 5 Sysol J, Machado R. Classification and pathophysiology of pulmonary hypertension. Continuing Cardiology Education 2018; 4: 2-12
• 6 Sadok A, Marshall CJ. Rho GTPases: masters of cell migration. Small GTPases 2014; 5: e983878
• 7 Hodge RG, Ridley AJ. Regulating Rho GTPases and their regulators. Nature reviews Molecular cell biology 2016; 17: 496
• 8 Connolly MJ, Aaronson PI. Key role of the RhoA/Rho kinase system in pulmonary hypertension. Pulmonary pharmacology & therapeutics 2011; 24: 1-14
• 9 Guilluy C, Eddahibi S, Agard C. et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. American journal of respiratory and critical care medicine 2009; 179: 1151-1158
• 10 Firth AL, Choi I-W, Park WS. Animal models of pulmonary hypertension: Rho kinase inhibition. Progress in biophysics and molecular biology 2012; 109: 67-75
• 11 Zhang Y, Wu S. Effects of fasudil on pulmonary hypertension in clinical practice. Pulmonary pharmacology & therapeutics 2017; 46: 54-63
• 12 Kamei S, Oishi M, Takasu T. Evaluation of fasudil hydrochloride treatment for wandering symptoms in cerebrovascular dementia with 31P-magnetic resonance spectroscopy and Xe-computed tomography. Clinical neuropharmacology 1996; 19: 428-438
• 13 Liu GJ, Wang ZJ, Wang YF. et al. Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. European journal of clinical pharmacology 2012; 68: 131-139
• 14 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 2009; 6: e1000097
• 15 Berkman ND, Lohr KN, Ansari M. et al. Grading the strength of a body of evidence when assessing health care interventions for the effective health care program of the Agency for Healthcare Research and Quality: an update. Methods Guide for Effectiveness and Comparative Effectiveness Reviews [Internet]. 2013
• 16 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. Bmj 2003; 327: 557-560
• 17 Tarsilla M. Cochrane handbook for systematic reviews of interventions. Journal of Multidisciplinary Evaluation 2008; 6: 142-148
• 18 Egger M, Smith GD, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. Bmj 1997; 315: 629-634
• 19 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 1088-1101
• 20 Fujita H, Fukumoto Y, Saji K. et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart and vessels 2010; 25: 144-149
• 21 Fukumoto Y, Matoba T, Ito A. et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91: 391-392
• 22 Fukumoto Y, Yamada N, Matsubara H. et al. Double-Blind, Placebo-Controlled Clinical Trial With a Rho-Kinase Inhibitor in Pulmonary Arterial Hypertension–A Pilot Efficacy Trial–. Circulation Journal 2013; 77: 2619-2625
• 23 Ishikura K, Yamada N, Ito M. et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circulation Journal 2006; 70: 174-178
• 24 Jiang R, Ai Z-S, Jiang X. et al. Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. Hypertension Research 2015; 38: 539-544
• 25 Jiang X, Wang Y-F, Zhao Q-H. et al. Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study. International journal of cardiology 2014; 177: 61-65
• 26 Kojonazarov B, Myrzaakhmatova A, Sooronbaev T. et al. Effects of fasudil in patients with high-altitude pulmonary hypertension. European Respiratory Journal 2012; 39: 496-498
• 27 Li F, Xia W, Yuan S. et al. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pediatric cardiology 2009; 30: 363-366
• 28 Liu P, Zhang H, Tang Y. et al. Influence of Rho kinase inhibitor Fasudil on late endothelial progenitor cells in peripheral blood of COPD patients with pulmonary artery hypertension. Bratislavske lekarske listy 2015; 116: 150-153
• 29 Ruan H, Zhang Y, Liu R. et al. The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension. Congenital heart disease 2019; 14: 645-650
• 30 J-w Xiao, X-y Zhu, Q-g Wang. et al. Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects. Circulation Journal 2015; CJ- 14-1015
• 31 Zhang X, Zhang X, Wang S. et al. Effects of fasudil on patients with pulmonary hypertension associated with left ventricular heart failure with preserved ejection fraction: a prospective intervention study. Canadian Respiratory Journal 2018; 3148259
• 32 Yaghi S, Novikov A, Trandafirescu T. Clinical update on pulmonary hypertension. Journal of Investigative Medicine 2020; 68: 821-827
• 33 Barnes H, Brown Z, Burns A. et al. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database of Systematic Reviews. 2019
• 34 Mathier MA, Ishizawar D. Bosentan. Expert opinion on pharmacotherapy 2010; 11: 1023-1034
• 35 Zhao J, Zhou D, Guo J. et al. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. Neurologia medico-chirurgica 2011; 51: 679-683
• 36 Suzuki Y, Shibuya M, Satoh S-i. et al. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surgical neurology 2007; 68: 126-131
• 37 Guglin M, Mehra S, Mason TJ. Comparison of drugs for pulmonary hypertension reversibility testing: A meta-analysis. Pulmonary circulation 2013; 3: 406-413